Mesenchymal Stromal Cells (MSC´s) in Renal Lupus (MSC-ROLE)
Mesenchymal stem cells (MSCs) are derived from bone marrow and are capable of differentiating into a variety of mesenchymal lineages and also possess immune-modulatory capabilities. They have emerged as a potentially beneficial therapy for Lupus nephritis by reducing autoimmune activities through immunomodulatory effects.
Enroll in this clinical study
How are MSCs being studied in Lupus nephritis?
The dose-response and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Renal Systemic Lupus Erythematosus is being studied in this Phase IIa trial of escalating doses of intravenous MSCs in active SLE, followed by a Phase IIb, triple-blind, controlled assessment of the selected MSC dosing versus Placebo, in SLE patients receiving Standard of Care Therapy for Severe Renal Disease.
Eligibility Criteria
Inclusion criteria:
Aged 18-75 years
Class III or IV proliferative disease (ISN/RPS) Renal Biopsy within 12 months plus Active Urinary Sediment (> 5 red blood cells/high-power field and/or >8 white blood cells/high-power field and/or cylindruria during the current flare).
Urine protein creatinine ratio ≥ 1